Search
Powered By HealthLine
Health Tools
 Mood Tracker
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Prostate Cancer Treatment May Have Downside

Ivanhoe Newswire


Related Encyclopedia
 border=
Ankylosing Spondylitis
Baldness
Bechterew's Disease (Ankylosing spondylitis)
Benign Prostatic Hyperplasia
More...

Related Healthscout Videos
 border=
Don't Wait on Your Prostate
The Rise of Cancer
Doubling Prostate Cancer Survival
HPV: The New Kissing Disease?
More...

Related Animations
 border=
Erectile Dysfunction
More...

Related Drug Information
 border=
Cialis
Flomax
Topamax
Viagra
More...

Related News Articles
 border=
1 in 5 Pharmacies Hinders Teens' Access to 'Morning-After' Pill: Study
Understanding the Genetics of Colon Cancer
Hops may Prevent Prostate Cancer
H1N1 Deaths Comparable to Seasonal Flu
More...

(Ivanhoe Newswire) -- A common treatment given to men who suffer from aggressive prostate cancer may actually be helping those cancers migrate to other parts of the body.

Researchers from Johns Hopkins University came to that conclusion after studying the role androgen deprivation therapy plays in activating a protein called nestin. Anodrogen deprivation therapy slows tumor growth by depriving cancer cells of testosterone. Nestin is linked to cell growth and development.

Text Continues Below



The study was spurred when the researchers discovered nestin was active in prostate cancer cells grown in the laboratory. From there, they looked for nestin in prostate cancer cells taken from men with cancer that had not spread and in those with cancers that had spread. Nestin was not seen in the first group of men, but was evident in the second.

Since men usually dont receive androgen deprivation therapy unless their cancers are more aggressive, researchers decided the therapy may be fostering the development of the protein.

To further investigate, researchers studied prostate cancer cells that depend on androgens to grow and develop, finding those cells did indeed increase their production of nestin when deprived of androgen. From there they hampered nestin expression in some of the cells and compared them with cells allowed normal nestin expression. Cells with hampered nestin were less likely to migrate out of the cells than cells with normal nestin expression.

So, should men with prostate cancer stop taking androgen deprivation therapy? The researchers stop far short of that recommendation, noting the current findings are too preliminary to change clinical practice. However, they do believe their discovery warrants more study, noting, further investigation into this pathway and may identify novel points for intervention in metastatic prostate cancer.

This article was reported by Ivanhoe.com, which offers Medical Alerts by e-mail every day of the week. To subscribe, click on: http://www.ivanhoe.com/newsalert/.

SOURCE: Cancer Research, 2007;67:9199-9206




Last updated 10/4/2007

Related Links
 border=
From Healthscout's partner site on prostate, ProstateCommons.com
Prostate Check: Test yourself for symptoms online
Video: Prostate ultrasounds may save lives
Treatment: Get information about enlarged prostate treatments





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire